A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.
about
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVThe role of drug transporters in the kidney: lessons from tenofovirFrench 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistatAntiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileDolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionThe role of dolutegravir in the management of HIV infectionA consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Simultaneous determination of plasma creatinine, uric acid, kynurenine and tryptophan by high-performance liquid chromatography: method validation and in application to the assessment of renal function.Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging studyThe Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects.Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.Dolutegravir.Emerging antiretroviral drugs.Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.Dolutegravir, abacavir and lamivudine as HIV therapy.Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults.Evaluation of dolutegravir safety for the treatment of HIV-1.Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.Combination dolutegravir-abacavir-lamivudine in the management of HIV/AIDS: clinical utility and patient considerations.Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.The Complexities of Interpreting Reversible Elevated Serum Creatinine Levels in Drug Development: Does a Correlation with Inhibition of Renal Transporters Exist?Evaluation of the concurrent use of dolutegravir and metformin in human immunodeficiency virus-infected patients.Endogenous Probes for Drug Transporters: Balancing Vision With Reality.Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults.Renal effects of novel antiretroviral drugs.Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy.Abacavir + dolutegravir + lamivudine for the treatment of HIV.Renal Drug Transporters and Drug Interactions.The problem of renal function monitoring in patients treated with the novel antiretroviral drugs.Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.The association between urinary liver-type fatty acid-binding protein and chronic kidney disease classification in HIV-infected Japanese patients.
P2860
Q26778450-1E571C48-6B36-46CA-8AFB-BE01B6392397Q26799712-083AF2DE-F35B-44D0-8510-12B2081333E1Q26866489-99C1ADE6-2A5E-4BF4-9582-5052F5FD753DQ33775397-109F7A3D-F895-4A05-8AF9-660896D03DD3Q33880418-DC99DF0A-2896-4ECA-BD07-C02FCDEBC629Q33997420-14D2D43A-BA86-45C5-B824-CA4810A7A1ECQ34540677-39D4EBD0-DBC1-46C8-81AB-E321B9A46F15Q34726183-FEF9043C-E4D5-481C-9550-9DBFF3BBD4E0Q34976284-5BF323EE-614F-498B-A8CA-4F7C0666A0CAQ35121450-0DF98B0A-33E4-41F8-ACCD-79CC3BC28C48Q35149475-5D8D6421-D37D-49EB-AA91-4C8E49DCCFA6Q35209656-160C5FDD-551E-4A52-943C-0911922755FEQ36959425-0C118093-604C-400D-BFDA-B0EFE07422F5Q37071977-63F3AC56-1DD9-4F5D-A6B4-4DD65C1C8D49Q37242504-211F1478-5FD9-4937-8CBA-49A0CBA4B013Q37248656-226A2EDA-AF6D-4D25-9D9D-634CB5C1E793Q37614157-385CBCA6-D007-40E7-B9A2-21FFA9FDC138Q38167382-FA8AAA1B-2B55-4A92-934E-BC9810C3F705Q38172029-EF225C85-024A-41EA-92F6-4FAD53A6F78FQ38203844-3451EA8C-C3D1-4E74-B05D-96A14884D5C9Q38206232-E893366D-BE0B-4807-99BB-419ACE59CECFQ38227491-0B5934C1-22BE-442A-833B-4652165AFB85Q38262935-89AE8AE3-6F13-4D8B-95F2-B4A0BACE7832Q38263322-8E9CC365-BE04-4CC8-BBBE-008F2ED1DA14Q38324557-58F7B14A-56C2-480C-9903-F0B07EAEDDE7Q38362394-F810B1E9-A144-4853-9A5E-FF7692761CFCQ38367106-39B47BDD-7700-46F6-AE2B-CE442B655E6BQ38541809-4CC88CC6-A81C-47CD-8CCA-574C5A54282AQ38601891-40898B3D-18EE-4FCF-97E6-41E2FBCD8D99Q38716267-3CE464E8-BCB3-4B45-95D5-615991B69AA8Q38717417-2D42DB16-75B3-4CDC-B6F8-30B3752D6482Q38754924-08E13275-22E8-4B9E-A822-017933DDDFFDQ38811626-2A8CF0CD-8869-4B10-97D7-7F6DB80FFF15Q38837077-07B64D9A-717A-442F-AD3C-86FA73E8E5D7Q38920747-D9F860A4-7052-46EA-98E6-E1CDC725BE31Q38951349-F1EB4888-3632-4773-9C94-96E7C3EA010DQ39140289-3E609F89-4E4D-4907-94C9-55BCA81F3365Q39203030-2D6EA46A-0398-4A43-B409-5DA6CE65B3C7Q40103229-6A4AA566-F5BF-4C95-BE43-430257A96913Q40497483-CDAB827F-3A57-4A24-89F5-B529B1C00D14
P2860
A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A phase 1 study to evaluate th ...... clearance in healthy subjects.
@ast
A phase 1 study to evaluate th ...... clearance in healthy subjects.
@en
type
label
A phase 1 study to evaluate th ...... clearance in healthy subjects.
@ast
A phase 1 study to evaluate th ...... clearance in healthy subjects.
@en
prefLabel
A phase 1 study to evaluate th ...... clearance in healthy subjects.
@ast
A phase 1 study to evaluate th ...... clearance in healthy subjects.
@en
P2093
P2860
P1476
A phase 1 study to evaluate th ...... clearance in healthy subjects.
@en
P2093
Amanda Peppercorn
Courtney Cannon
Heather Muster
Julie Borland
Justin Koteff
Shuguang Chen
Stephen C Piscitelli
Takaaki Koshiba
P2860
P304
P356
10.1111/J.1365-2125.2012.04440.X
P407
P577
2013-04-01T00:00:00Z